A Practitioner’s Guide to Prescribing Oxcarbazepine for Adults with Intellectual Disabilities

  • Jose de Leon
Chapter
First Online:

Abstract

We developed this oxcarbazepine guideline using drug prescribing ­information and reviewing the available literature on relevant neuropsychiatric ­disorders in populations without intellectual disabilities because of the dearth of available literature on the population with intellectual disabilities. This guideline includes indications; contraindications; assessments prior to and during treatment; dosing with particular focus on dosing modifications required by drug–drug interactions, or personal characteristics; and adverse drug reactions. The procedures contained in this guideline may not fully account for all of the possible risks of treatment in this population because of the limited studies available; thus, there will be a need to periodically update this guideline as new information becomes available. Nevertheless, we believe that this guideline provides a useful resource for clinicians who treat epilepsy in adult individuals with intellectual disabilities. An oxcarbazepine drug utilization review that summarizes this guideline is described.

Keywords

Bipolar Disorder Intellectual Disability Therapeutic Drug Monitoring Trigeminal Neuralgia Potential DDIs 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.

References

  1. Anderson, G. D. (1998). A mechanistic approach to antiepileptic drug interactions. The Annals of Pharmacotherapy, 32, 554–563.PubMedCrossRefGoogle Scholar
  2. Andreasen, A. H., Brøsen, K., & Damkier, P. (2007). A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4. Epilepsia, 48, 490–496.PubMedCrossRefGoogle Scholar
  3. Arana, A., Wentworth, C. E., Ayuso-Mateos, J. L., & Arellano, F. M. (2010). Suicide-related events in patients treated with antiepileptic drugs. The New England Journal of Medicine, 363, 542–551.PubMedCrossRefGoogle Scholar
  4. Arif, H., Buchsbaum, R., Pierro, J., Whalen, M., Sims, J., & Resor, S. R., Jr., et al. (2010). Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Archives of Neurology, 67, 408–415.PubMedCrossRefGoogle Scholar
  5. Arif, H., Buchsbaum, R., Weintraub, D., Koyfman, S., Salas-Humara, C., & Bazil, C. W., et al. (2007). Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology, 68, 1701–1709.PubMedCrossRefGoogle Scholar
  6. Arif, H., Buchsbaum, R., Weintraub, D., Pierro, J., Resor, S. R., Jr., & Hirsch, L. J. (2009). Patient-reported cognitive side effects of antiepileptic drugs: predictors and comparison of all commonly used antiepileptic drugs. Epilepsy Behavior, 14, 202–209.PubMedCrossRefGoogle Scholar
  7. Baird, P. (2003). The interactive metabolism effect of oxcarbazepine coadministered with tricyclic antidepressant therapy for OCD symptoms (letter). Journal of Clinical Psychopharmacology, 23, 419–420.PubMedCrossRefGoogle Scholar
  8. Baruzzi, A., Albani, F., & Riva, R. (1994). Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia, 35(Suppl 3), S14–S19.PubMedCrossRefGoogle Scholar
  9. Bell, G. S., Mula, M., & Sander, J. W. (2009). Suicidality in people taking antiepileptic drugs: what is the evidence? CNS Drugs, 23, 281–292.PubMedCrossRefGoogle Scholar
  10. Benedetti, M. S., Whomsley, R., Baltes, E., & Tonner, F. (2005). Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucurunosyltransferase induction. European Journal of Clinical Pharmacology, 61, 863–872.PubMedCrossRefGoogle Scholar
  11. Bring, P., & Ensom, M. H. (2008). Does oxcarbazepine warrant therapeutic drug monitoring? A critical review. Clinical Pharmacokinetics, 47, 767–778.PubMedCrossRefGoogle Scholar
  12. Brodie, M. J. (2010). Antiepileptic drug therapy the story so far. Seizure, 19, 650–655.PubMedCrossRefGoogle Scholar
  13. Buggy, Y., Layton, D., Fogg, C., & Shakir, S. A. (2010). Safety profile of oxcarbazepine: results from a prescription-event monitoring study. Epilepsia, 51, 818–289.PubMedGoogle Scholar
  14. Castillo, S., Schmidt, D.B., White, S. (2000) Oxcarbazepine add-on for drug-resistant partial epilepsy. The Cochrane Database Systematic Reviews, 3, CD002028.Google Scholar
  15. Deb, S., Bramble, D., Drybala, G., Boyle, A., & Bruce, J. (1994). Polydipsia amongst adults with a learning disability in an institution. Journal of Intellectual Disability Research, 38, 359–367.PubMedCrossRefGoogle Scholar
  16. Degen, P. H., Flesch, G., Cardot, J. M., Czendlik, C., & Dieterle, W. (1994). The influence of food on the disposition of the antiepileptic oxcarbazepine and its major metabolites in healthy volunteers. Biopharmaceutics and Drug Disposition, 15, 519–526.CrossRefGoogle Scholar
  17. de Leon, J., Armstrong, S. C., & Cozza, K. L. (2005). The dosing of atypical antipsychotics. Psychosomatics, 46, 262–273.PubMedCrossRefGoogle Scholar
  18. de Leon, J., Verghese, C., Tracy, J., Josiassen, R., & Simpson, G. M. (1994). Polydipsia and water intoxication in psychiatric patients: a review of the epidemiological literature. Biological Psychiatry, 35, 408–419.PubMedCrossRefGoogle Scholar
  19. Dogan, E. A., Usta, B. E., Bilgen, R., Senol, Y., & Aktekin, B. (2008). Efficacy, tolerability, and side effects of oxcarbazepine monotherapy: a prospective study in adult and elderly patients with newly diagnosed partial epilepsy. Epilepsy Behavior, 13, 156–161.PubMedCrossRefGoogle Scholar
  20. Dong, X., Leppik, I. E., White, J., & Rarick, J. (2005). Hyponatremia from oxcarbazepine and carbamazepine. Neurology, 65, 1976–1978.PubMedCrossRefGoogle Scholar
  21. Eisenberg, E., River, Y., Shifrin, A., & Krivoy, N. (2007). Antiepileptic drugs in the treatment of neuropathic pain. Drugs, 67, 1265–1289.PubMedCrossRefGoogle Scholar
  22. Fountoulakis, K. N., & Vieta, E. (2008). Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. The International Journal of Neuropsychopharmacology, 11, 999–1029.PubMedGoogle Scholar
  23. Goodnick, P. J. (2006). Anticonvulsants in the treatment of bipolar mania. Expert Opinion on Pharmacotherapy, 7, 401–410.PubMedCrossRefGoogle Scholar
  24. Gualtieri, C.T., Johnson, L.G. (2006) Comparative neurocognitive effects of 5 psychotropic anticonvulsants and lithium. Medscape General Medicine 23, 8:46.Google Scholar
  25. Harris, E. C., & Barraclough, B. (1997). Suicide as an outcome for mental disorders. A meta-analysis. The British Journal of Psychiatry, 170, 205–228.PubMedCrossRefGoogle Scholar
  26. Hesdorffer, D. C., Berg, A. T., & Kanner, A. M. (2010). An update on antiepileptic drugs and suicide: are there definitive answers yet? Epilepsy Current, 10, 137–145.CrossRefGoogle Scholar
  27. Högler, W., Wudy, S. A., Luef, G., Hartmann, M. F., & Rauchenzauner, M. (2010). Oxcarbazepine accelerates cortisol elimination via cytochrome P450 3A4 induction. Archives of Disease in Childhood, 95, 1065.PubMedCrossRefGoogle Scholar
  28. Huband, N., Ferriter, M., Nathan, R., Jones, H. (2010) Antiepileptics for aggression and associated impulsivity. The Cochrane Database Systematic Reviews, 2, CD003499.Google Scholar
  29. Jorns, T. P., & Zakrzewska, J. M. (2007). Evidence-based approach to the medical management of trigeminal neuralgia. British Journal of Neurosurgery, 21, 253–261.PubMedCrossRefGoogle Scholar
  30. Juruena, M. F., Ottoni, G. L., Machado-Vieira, R., Carneiro, R. M., Weingarthner, N., & Marquardt, A. R., et al. (2009). Bipolar I and II disorder residual symptoms: oxcarbazepine and carbamazepine as add-on treatment to lithium in a double-blind, randomized trial. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 94–99.PubMedCrossRefGoogle Scholar
  31. Kakkar, A. K., Rehan, H. S., Unni, K. E., Gupta, N. K., Chopra, D., & Kataria, D. (2009). Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. European Psychiatry, 24, 178–182.PubMedCrossRefGoogle Scholar
  32. Kalanin, V. V. (2007). Suicidality and antiepileptic drugs. Is there a link? Drug Safety, 30, 123–142.CrossRefGoogle Scholar
  33. Kapetanovic, S. (2007). Oxcarbazepine in youths with autistic disorder and significant disruptive behaviors (letter). The American Journal of Psychiatry, 164, 832–833.PubMedCrossRefGoogle Scholar
  34. Kaussner, Y., Kenntner-Mabiala, R., Hoffmann, S., Klatt, J., Tracik, F., & Krüger, H. P. (2010). Effects of oxcarbazepine and carbamazepine on driving ability: a double-blind, randomized crossover trial with healthy volunteers. Psychopharmacology, 210, 53–63.PubMedCrossRefGoogle Scholar
  35. Ketter, T. A., Wang, P. W., & Post, R. M. (2009). Carbamazepine and oxcarbazepine. In A. F. Schatzberg & C. B. Nemeroff (Eds.), The American Psychiatric Publishing textbook of psychopharmacology (4th ed., pp. 735–765). Washington: DC, American Psychiatric Publishing.Google Scholar
  36. Koch, M.W., Polman, S.K. (2009) Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. The Cochrane Database Systematic Reviews, 4, CD006453.Google Scholar
  37. Knudsen, J. F., Flowers, C. M., Kortepeter, C., & Awaad, Y. (2007). Clinical profile of oxcarbazepine-related angioneurotic edema: case report and review. Pediatric Neurology, 37, 134–137.PubMedCrossRefGoogle Scholar
  38. Kuehn, B. M. (2008). FDA warns of adverse events linked to smoking cessation drug and antiepileptics. The Journal of the American Medical Association, 299, 1121–1122.PubMedCrossRefGoogle Scholar
  39. Lacy, C. F., Armstrong, L. L., Goldman, M. P., & Lance, L. L. (2009). Drug information handbook (18th ed.). OH, Lexi-Comp, Inc: Hudson.Google Scholar
  40. Le Louët, H., Thomas, L., & Babai, S. (2008). DRESS: is oxcarbazepine safer than carbamazepine? An analysis of the French Pharmacovigilance database. European Journal of Neurology, 15, e43.PubMedCrossRefGoogle Scholar
  41. Lin, C. H., Lu, C. H., Wang, F. J., Tsai, M. H., Chang, W. N., & Tsai, N. W., et al. (2010). Risk factors of oxcarbazepine-induced hyponatremia in patients with epilepsy. Clinical Neuropharmacology, 33, 293–296.PubMedCrossRefGoogle Scholar
  42. Lloyd, P., Flesch, G., & Dieterle, W. (1994). Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia, 35(Suppl 3), S10–S13.PubMedCrossRefGoogle Scholar
  43. Lutz, U. C., Wiatr, G., Gaertner, H. J., & Bartels, M. (2007). Oxcarbazepine treatment during breast-feeding: a case report. Journal of Clinical Psychopharmacology, 27, 730–732.PubMedCrossRefGoogle Scholar
  44. Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., & Avoli, M. (2010). Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurology, 9, 413–424.PubMedCrossRefGoogle Scholar
  45. Marson, A. G., Al-Kharusi, A. M., Alwaidh, M., Appleton, R., Baker, G. A., & Chadwick, D. W. et al. (2007). The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblended randomised controlled trial. Lancet, 369, 1000–1015.CrossRefGoogle Scholar
  46. Mattes, J. A. (2005). Oxcarbazepine in patients with impulsive aggression: a double-blind, placebo-controlled trial. Journal of Clinical Psychopharmacology, 25, 575–579.PubMedCrossRefGoogle Scholar
  47. May, T. W., Rambeck, B., & Jurgens, U. (1999). Influence of oxcarbamazepine and methosuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Therapeutic Drug Monitoring, 21, 175–181.PubMedCrossRefGoogle Scholar
  48. May, T. W., Rambeck, B., & Jürgens, U. (2002). Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. Therapeutic Drug Monitoring, 24, 366–374.PubMedCrossRefGoogle Scholar
  49. May, T. W., Korn-Merker, E., & Rambeck, B. (2003). Clinical pharmacokinetics of oxcarbazepine. Clinical Pharmacokinetics, 42, 1023–1042.PubMedCrossRefGoogle Scholar
  50. Mazza, M., Della Marca, G., Di Nicola, M., Martinotti, G., Pozzi, G., & Janiri, L., et al. (2007). Oxcarbazepine improves mood in patients with epilepsy. Epilepsy Behavior, 10, 397–401.PubMedCrossRefGoogle Scholar
  51. Mazza, M., Di Nicola, M., Martinotti, G., Taranto, C., Pozzi, G., & Conte, G., et al. (2007). Oxcarbazepine in bipolar disorder: a critical review of the literature. Expert Opinion on Pharmacotherapy, 8, 649–656.PubMedCrossRefGoogle Scholar
  52. Mazzucchelli, I., Onat, F. Y., Ozkara, C., Atakli, D., Specchio, L. M., & Neve, A. L., et al. (2006). Changes in the disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia, 47, 504–509.PubMedCrossRefGoogle Scholar
  53. McKee, P. J., Blacklaw, J., Forrest, G., Gillham, R. A., Walker, S. M., & Connelly, D., et al. (1994). A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. British Journal of Clinical Pharmacology, 37, 27–32.PubMedGoogle Scholar
  54. Merrick, J., Merrick, E., Lunsky, Y., & Kandel, I. (2006). A review of suicidality in persons with intellectual disability. The Israel Journal of Psychiatry and Related Sciences, 43, 258–264.Google Scholar
  55. Miller, J., & Carney, P. (2006). Central hypothyroidism with oxcarbazepine therapy. Pediatric Neurology, 34, 242–244.PubMedCrossRefGoogle Scholar
  56. Mintzer, S. (2010). Metabolic consequences of antiepileptic drugs. Current Opinion in Neurology, 23, 164–169.PubMedCrossRefGoogle Scholar
  57. Mintzer, S., Boppana, P., Toguri, J., & DeSantis, A. (2006). Vitamin D levels and bone turnover in epilepsy patients taking carbamazepine or oxcarbazepine. Epilepsia, 47, 510–515.PubMedCrossRefGoogle Scholar
  58. Mula, M., & Sander, J. W. (2007). Negative effects of antiepileptic drugs on mood in patients with epilepsy. Drug Safety, 30, 555–567.PubMedCrossRefGoogle Scholar
  59. Muller M, Marson AG, Williamson PR (2006) Oxcarbazepine versus phenytoin monotherapy for epilepsy. The Cochrane Database Systematic Reviews, 2, CD003615.Google Scholar
  60. Muscatello, M. R., Pacetti, M., Cacciola, M., La Torre, D., Zoccali, R., & D’Arrigo, C., et al. (2005). Plasma concentrations of risperidone and olanzapine during coadministration with oxcarbazepine. Epilepsia, 46, 771–774.CrossRefGoogle Scholar
  61. Nasreddine, W., & Beydoun, A. (2007). Oxcarbazepine in neuropathic pain. Expert Opinion on Investigational Drugs, 16, 1615–1625.PubMedCrossRefGoogle Scholar
  62. Novartis Pharmaceutical Corporation (2011) Highlights of prescribing information: Trileptal (oxcarbazepine) film-coated tablets. Trileptal (oxcarbazepine) oral suspension for oral administration. East Hanover, NJ: Novartis Pharmaceutical CorporationGoogle Scholar
  63. O’Neill, A., & de Leon, J. (2007). Two case reports of oral ulcers with lamotrigine several weeks after oxcarbazepine withdrawal. Bipolar Disorders, 9, 310–313.PubMedCrossRefGoogle Scholar
  64. Paliwal, V., Garg, R. K., Kar, A. M., & Singh, M. K. (2006). Oxcarbazepine induced hyponatremic coma. Neurology India, 54, 214–215.PubMedGoogle Scholar
  65. Patsalos, P. N., Berry, D. J., Bourgeois, B. F., Cloyd, J. C., Glauser, T. A., & Johannessen, S. I., et al. (2008). Antiepileptic drugs – best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia, 49, 1239–1276.PubMedCrossRefGoogle Scholar
  66. Patsalos, P. N., Zakrzewska, J. M., & Elyas, A. A. (1990). Dose dependent enzyme induction by oxcarbazepine? European Journal of Clinical Pharmacology, 39, 187–188.PubMedCrossRefGoogle Scholar
  67. Perucca, E. (2006). Clinically relevant drug interactions with antiepileptic drugs. British Journal of Clinical Pharmacology, 61, 246–255.PubMedCrossRefGoogle Scholar
  68. Petrenaite, V., Sabers, A., & Hansen-Schwartz, J. (2009). Seizure deterioration in women treated with oxcarbazepine during pregnancy. Epilepsy Research, 84, 245–249.PubMedCrossRefGoogle Scholar
  69. Popova, E., Leighton, C., Bernabarre, A., Bernardo, M., & Vieta, E. (2007). Oxcarbazepine in the treatment of bipolar and schizoaffective disorders. Expert Review of Neurotherapeutics, 7, 617–626.PubMedCrossRefGoogle Scholar
  70. Raitasuo, V., Lehtovaara, R., & Huttunen, M. O. (1994). Effect of carbamazepine to oxcarbazepine on the plasma levels of neuroleptics: a case report. Psychopharmacology, 116, 115–116.PubMedCrossRefGoogle Scholar
  71. Rogwaski, M. A., & Löscher, W. (2004). The neurobiology of antiepileptic drugs. Nature Reviews. Neuroscience, 5, 553–564.CrossRefGoogle Scholar
  72. Rouan, M. C., Lecaillon, J. B., Godbillon, J., Menard, F., Darragon, T., & Meyer, P., et al. (1994). The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. European Journal of Clinical Pharmacology, 47, 161–167.PubMedCrossRefGoogle Scholar
  73. Sabers, A. (2008). Pharmacokinetic interactions between contraceptives and antiepileptic drugs. Seizure, 17, 141–144.PubMedCrossRefGoogle Scholar
  74. Sachdeo, R. C., Wasserstein, A., Mesenbrink, P. J., & D’Souza, J. (2002). Effects of oxcarbazepine on sodium concentration and water handling. Annals of Neurology, 51, 613–620.PubMedCrossRefGoogle Scholar
  75. Saconato, H., Prado, G. F., Puga, M. E., & Atallah, A. N. (2009). Oxcarbazepine for refractory epilepsy: systematic review of the literature. São Paulo Medical Journal, 127, 150–159.PubMedGoogle Scholar
  76. Schmidt, D., & Elger, C. E. (2004). What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs? Epilepsy Behavior, 5, 627–635.PubMedCrossRefGoogle Scholar
  77. Sheth, R. D., & Montouris, G. (2008). Metabolic effects of AEDs: impact on body weight, lipids and glucose metabolism. International Review of Neurobiology, 83, 329–346.PubMedCrossRefGoogle Scholar
  78. Simister, R. J., Sander, J. W., & Koepp, M. J. (2007). Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy and Behavior, 2, 336–339.CrossRefGoogle Scholar
  79. Sirven, J. I., Fife, T. D., Wingerchuk, D. M., & Drazkowski, J. F. (2007). Second-generation ­antiepileptic drugs’ impact on balance: a meta-analysis. Mayo Clinic Proceedings, 82, 40–47.PubMedGoogle Scholar
  80. Sommer, B. R., Fenn, H. H., & Ketter, T. A. (2007). Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin. Expert Opinion on Drug Safety, 6, 133–145.PubMedCrossRefGoogle Scholar
  81. Soskin, D. P., Kane, A. J., & Stern, T. A. (2010). Phenytoin toxicity secondary to an oxcarbazepine-phenytoin 2C19 interaction. Psychosomatics, 51, 532–535.PubMedGoogle Scholar
  82. Spina, E. A., & de Leon, J. (2007). Metabolic drug interactions with newer antipsychotics: a comparative review. Basic and Clinical Pharmacology and Toxicology, 100, 4–22.PubMedCrossRefGoogle Scholar
  83. Tartara, A., Galimberti, C. A., Manni, R., Morini, R., Limido, G., & Gatti, G., et al. (1993). The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. British Journal of Clinical Pharmacology, 36, 366–368.PubMedGoogle Scholar
  84. Theis, J. G., Sidhu, J., Palmer, J., Job, S., Bullman, J., & Ascher, J. (2005). Lack of pharmacokinetic interaction between oxcarbazepine and lamotrigine. Neuropsychopharmacology, 30, 2269–2274.PubMedCrossRefGoogle Scholar
  85. Tomson, T., & Battino, D. (2007). Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium. Clinical Pharmacokinetics, 46, 209–219.PubMedCrossRefGoogle Scholar
  86. US Department of Mental Health and Human Services (2008) Statistical review and evaluation: antiepileptic drugs and suicidality. http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4372b1-01-FDA.pdf. Accessed 5 April 2011.
  87. Vasudev, A., Macritchie, K., Watson, S., Geddes, J.R., Young, A.H. (2008) Oxcarbazepine in the maintenance treatment of bipolar disorder. The Cochrane Database Systematic Reviews, 1, CD005171.Google Scholar
  88. Vieta, E., Cruz, N., García-Campayo, J., de Arce, R., Manuel Crespo, J., & Vallès, V., et al. (2008). A double-blind, randomized, placebo-controlled prophylaxis trial of oxcarbazepine as adjunctive treatment to lithium in the long-term treatment of bipolar I and II disorder. The International Journal of Neuropsychopharmacology, 11, 445–452.PubMedCrossRefGoogle Scholar
  89. Weintraub, D., Buchsbaum, R., Resor, S. R., Jr., & Hirsch, L. J. (2005). Effect of antiepileptic drug comedication on lamotrigine clearance. Archives of Neurology, 62, 1432–1436.PubMedCrossRefGoogle Scholar
  90. Xiong, G. L., Ferranti, J., & Leamon, M. H. (2008). Toxic interaction between valproate and oxcarbazepine: a case detected by the free valproate level. Journal of Clinical Psychopharmacology, 28, 472–473.PubMedCrossRefGoogle Scholar
  91. Zaccara, G., Gangemi, P. F., Bendoni, L., Menge, G. P., Schwabe, S., & Monza, G. C. (1993). Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Therapeutic Drug Monitoring, 15, 39–42.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Jose de Leon
    • 1
  1. 1.Department of Psychiatry College of MedicineUniversity of KentuckyLexingtonUSA

Personalised recommendations